WINTON GROUP Ltd Buys Shares of 8,097 Inspire Medical Systems, Inc. (NYSE:INSP)

WINTON GROUP Ltd purchased a new position in Inspire Medical Systems, Inc. (NYSE:INSP) in the 2nd quarter, Holdings Channel reports. The firm purchased 8,097 shares of the company’s stock, valued at approximately $1,084,000.

Several other hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP increased its holdings in Inspire Medical Systems by 46.4% in the 4th quarter. Wellington Management Group LLP now owns 1,430,266 shares of the company’s stock worth $290,959,000 after buying an additional 453,294 shares in the last quarter. Frontier Capital Management Co. LLC grew its stake in shares of Inspire Medical Systems by 105.2% in the fourth quarter. Frontier Capital Management Co. LLC now owns 742,046 shares of the company’s stock worth $150,954,000 after acquiring an additional 380,362 shares during the period. Norges Bank purchased a new position in shares of Inspire Medical Systems during the fourth quarter valued at approximately $49,116,000. Baillie Gifford & Co. raised its holdings in shares of Inspire Medical Systems by 19.3% during the first quarter. Baillie Gifford & Co. now owns 1,467,613 shares of the company’s stock valued at $315,229,000 after purchasing an additional 237,734 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Inspire Medical Systems by 49.5% during the first quarter. Bank of New York Mellon Corp now owns 595,577 shares of the company’s stock valued at $127,924,000 after purchasing an additional 197,097 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 800 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Shawn Mccormick sold 800 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the transaction, the director now owns 23,140 shares in the company, valued at $5,090,800. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Randy Ban sold 4,861 shares of Inspire Medical Systems stock in a transaction on Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the completion of the sale, the insider now owns 3,056 shares in the company, valued at $576,208.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,692 shares of company stock valued at $1,099,207. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on INSP shares. Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a research note on Wednesday, August 7th. Stifel Nicolaus lowered their target price on Inspire Medical Systems from $210.00 to $170.00 and set a “hold” rating on the stock in a report on Monday, June 24th. Leerink Partners boosted their price target on Inspire Medical Systems from $167.00 to $197.00 and gave the company a “market perform” rating in a research note on Tuesday, September 10th. Morgan Stanley lowered their price objective on shares of Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating on the stock in a research note on Monday, July 15th. Finally, Robert W. Baird dropped their price objective on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $214.85.

Inspire Medical Systems Price Performance

Shares of INSP stock opened at $203.99 on Monday. The company has a market capitalization of $6.08 billion, a price-to-earnings ratio of -370.89 and a beta of 1.33. The company’s fifty day moving average price is $168.99 and its 200-day moving average price is $181.09. Inspire Medical Systems, Inc. has a one year low of $123.00 and a one year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.46. The business had revenue of $195.89 million for the quarter, compared to analysts’ expectations of $189.08 million. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The business’s quarterly revenue was up 29.6% on a year-over-year basis. During the same period last year, the firm earned ($0.41) earnings per share. Equities research analysts expect that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.